COMBINATIONS (TRIO) → INHALED CORTICOSTEROID + LONG-ACTING MUSCARINIC ANTAGONIST + LONG-ACTING BETA-2 AGONIST (ICS + LAMA + LABA) → BreztriTM

BreztriTM

COMBINATIONS (TRIO)

INHALED CORTICOSTEROID + LONG-ACTING MUSCARINIC ANTAGONIST + LONG-ACTING BETA-2 AGONIST (ICS + LAMA + LABA)

  • Class

    • Inhaled corticosteroid (ICS)
      Long-acting muscarinic antagonist (LAMA)
      Long-acting beta-2 agonist (LABA)

  • Active ingredient

    • Budesonide


    • Glycopyrronium (as bromide)


    • Formoterol fumarate dihydrate

  • Device

  • Age

    • 18 +

  • Typical use

    • Asthma
      no common use

    Asthma management principles

    • COPD
      exacerbation on dual bronchodilation (LAMA/LABA)

    COPD management principles

  • Marketed strength

    • 160/7.2/5 mcg

  • Number of doses

    • 120 doses

  • Dose indicator

    • Yes | Indicator

  • Usual adult dosage

    • Medium | 160/7.2/5 mcg – 2 inh BID

    ICS dosing

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • < 30 L/min
      Zero internal resistance (R0)

    Inspiratory flows

  • Public coverage

    • All provinces except YT | Restricted Benefit with criteria
      YT | Not a Benefit 

    Provincial coverage criteria

  • Advantages

    • Suitable for low inspiratory flows
    • All the daily medication in one inhaler
    • No synchronism required with a spacer

  • Disadvantages

    • BID dosing
    • Cumbersome with a spacer
    • Contain greenhouse gases
    Side effects

Product monograp

Download

Breztri(TM)'s website

Click to learn more

Trelegy®

Ellipta®

Enerzair®

Breezhaler®

Search for other inhalers

Explore the full list